Prime Medicine's CGD Therapy PM359 Gains FDA RMAT Designation
Event summary
- Prime Medicine's PM359 received FDA RMAT designation on June 22, 2026.
- Designation based on Phase 1/2 clinical data published in The New England Journal of Medicine.
- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.
- Therapy targets p47phox-deficient Chronic Granulomatous Disease (CGD).
- RMAT designation enables early FDA engagement and expedited review process.
The big picture
Prime Medicine's RMAT designation for PM359 underscores the growing momentum in gene editing therapies for rare diseases. The expedited regulatory pathway could position PM359 as a potential first-in-class treatment for CGD, addressing significant unmet medical needs. This development also highlights the strategic value of Prime Medicine's proprietary Prime Editing platform in developing transformative genetic therapies.
What we're watching
- Regulatory Pathway
- How the RMAT designation will accelerate PM359's path to Biologics License Application.
- Clinical Efficacy
- Whether Phase 1/2 data translates into long-term durability and safety for CGD patients.
- Pipeline Expansion
- The pace at which Prime Medicine advances other programs in Wilson Disease and Alpha-1 Antitrypsin Deficiency.
Related topics